VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Vaccine Mechanisms
Vaximmutordb
Vaxism
Vaxar
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UMMS Logo

Vaccine Detail

Influenza virus DNA vaccine d1TTFC-NP encoding NP
Vaccine Information
  • Vaccine Name: Influenza virus DNA vaccine d1TTFC-NP encoding NP
  • Target Pathogen: Influenza virus
  • Target Disease: Influenza (flu)
  • Vaccine Ontology ID: VO_0004306
  • Type: DNA vaccine
  • Status: Research
  • Host Species as Laboratory Animal Model: Mouse
  • NP gene engineering:
    • Type: DNA vaccine construction
    • Description: Vector pcDNA3.1 expressed influenza A nucleonucleoprotein epitope (amino acids 366–374; NP366) fused to the carboxy terminus of a tetanus toxin fragment (d1TTFC-NP) (Bins et al., 2005).
    • Detailed Gene Information: Click Here.
  • DNA vaccine plasmid: pcDNA3.1 DNA vaccine plasmid
  • Immunization Route: Intradermal injection (i.d.)
Host Response

Mouse Response

  • Vaccine Immune Response Type: VO_0000286
  • Efficacy: This vaccination strategy confers protecting humoral immunity against influenza A infection within 2 weeks after the start of vaccination. In the week after infection, mice that had previously been exposed to influenza A virus showed a minimal weight loss (1% at day 4 after infection). In contrast, mice given tattoo vaccination with the control plasmid or given an intramuscular injection of the hemagglutinin construct showed a sizable (10% and 14%, respectively) drop in body weight. Notably, mice that had received a short-interval hemagglutinin tattoo were largely protected from influenza A−induced morbidity (maximal weight loss of 4%; Student t-test, P = 0.039 versus control vaccine). The protection correlated with the induction of neutralizing antibodies. Furthermore, intradermal DNA tattooing also conferred long-term (4 months) protection (Bins et al., 2005).
References
Bins et al., 2005: Bins AD, Jorritsma A, Wolkers MC, Hung CF, Wu TC, Schumacher TN, Haanen JB. A rapid and potent DNA vaccination strategy defined by in vivo monitoring of antigen expression. Nature medicine. 2005; 11(8); 899-904. [PubMed: 15965482].